8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 3, 2005

Illumina, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	000-30361	330804655
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
9885 Towne Centre Drive, San Diego, California		92121
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 858 202 4500

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective June 6, 2005, Christian Henry has been appointed Vice President and Chief Financial Officer of Illumina, Inc. (the "Company"). In connection with his appointment, the Company and Mr. Henry executed an employment offer letter dated April 26, 2005, which provides for the employment of Mr. Henry on an at-will basis with an annual salary of $240,000, as well as customary relocation compensation. Mr. Henry is also eligible for a maximum annual bonus of 25% of his base salary. Mr. Henry will also be granted an option to purchase 100,000 shares of the Company's common stock at an exercise price equal to the fair market value of the Company's common stock on the first day of employment. The option has a 10-year term, with 20% of the shares vesting after one year and 1.67% of the shares vesting each month thereafter, so long as Mr. Henry continues to be employed by the Company.

A copy of the press release dated May 3, 2005 announcing Mr. Henry's appointment as the Company's Vice President and Chie f Financial Officer is attached as Exhibit 99.1, hereto and incorporated by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Illumina, Inc.
May 4, 2005	By:	Jay Flatley
		Name: Jay Flatley
		Title: Chief Executive Officer

Exhibit Index

Exhibit No.	Description
99.1	Press release, dated May 3, 2005, announcing the appointment of Christian Henry to the position of Vice President and Chief Financial Officer.

EX-99.1

Exhibit 99.1

ILLUMINA APPOINTS CHRISTIAN HENRY AS CHIEF FINANCIAL OFFICER

SAN DIEGO, CALIFORNIA, May 3, 2005 — Illumina, Inc. (NASDAQ: ILMN) announced today the appointment of Christian Henry to the position of Vice President and Chief Financial Officer, effective June 6, 2005. In this position, Mr. Henry will be responsible for worldwide financial operations, controllership functions and facilities management.

Mr. Henry has most recently served as the Chief Financial Officer for Tickets.com, a publicly traded, online ticket provider that was recently acquired by Major League Baseball Advanced Media, LP. Prior to that, Mr. Henry was Vice President, Finance and Corporate Controller of Affymetrix, Inc., a publicly traded life sciences company, where he oversaw accounting, planning, SEC and management reporting, treasury and risk management. He previously held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry received a BA in biochemistry and cell biology from the University of California, San Diego, and an MBA from the University of California, Irvine. He is a certified public accountant.

“Christian brings broad operations experience in finance as well as direct experience in the life science marketplace,” declared Jay Flatley, Illumina President and CEO. “We are excited to have Christian join our team and continue to enhance our financial management capabilities.”

Mr. Henry will replace Timothy Kish, whose last day with the Company was April 29, 2005. Mr. Kish served five years as Illumina’s Chief Financial Officer and has agreed to provide consulting services to the Company to ensure a smooth transition. “Tim has provided enormous contributions to Illumina and we wish him and his family the very best as they return to the East Coast,” stated Flatley.

About Illumina
Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company’s proprietary BeadArrayÔ technology — now used in leading genome centers around the world — provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix, Illumina’s ability to further develop and commercialize its Infinium assay and BeadArray^™ platform technologies, to deploy new gene expression and genotyping products and applications for its platform technology, to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company’s collaboration with Invitrogen, to scale, integrate and commercialize the CyVera technology, to manufacture robust Sentrix^® arrays and Oligator^® oligonucleotides, and other factors detailed in the Company’s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

# # #

Contacts: Jay Flatley
President & CEO
1.858.202.4501
jflatley@illumina.com William Craumer
Director, Corporate Communications
1.858.202.4667
bcraumer@illumina.com